Phytochemical investigation of the ethyl acetate-soluble fraction of stem bark extract of an African medicinal plant Terminalia brownii led to the isolation of a new oleanane-type triterpenoid, along with seven known triterpenoids, seven ellagic acid derivatives, and 3-O-β-D-glucopyranosyl-β-sitosterol. The new compound was identified using spectroscopic methods, notably 1D-and 2D NMR, as 3β,24-O-ethylidenyl-2α,19α-dihydroxyolean-12-en-28-oic acid. The isolated compounds were evaluated for their antimicrobial and antiplasmodial activities. Two compounds with a galloyl group (4 and 6) were found to be active against chloroquine sensitive (D6) and chloroquine resistant (W2) strains of Plasmodium falciparum, whereas three ellagic acid derivatives (5-7) were found active against three species of fungi and one species of bacteria.
Owing to the extensive use of T. brownii in traditional medicine and the observed activity of its extracts, we have investigated it for antiparasitic and antimicrobial constituents. Therefore, this communication reports the isolation of oleanane-type triterpenoids and ellagic acid derivatives from the plant, and evaluation of their antiplasmodial and antimicrobial activities. We also report the first isolation of 3β,24-O-ethylidenyl-2α,19α-dihydroxyolean-12-en-28oic acid (1) from either a natural or synthetic source.
Antiplasmodial evaluation of the fractions obtained from liquidliquid partitioning of the EtOH extract from the stem bark of T. brownii indicated that activity was concentrated in the ethyl acetate fraction. Chromatographic procedures on this fraction, as described in the Experimental Section, yielded fifteen known compounds and one new oleanane-type triterpenoid (1) . The known compounds isolated were identified using NMR and MS data, and by comparison with published data for arjunic acid (2) [11] , sericic acid (3) [12], 23-galloylarjunic acid (4) [13] , tomentosic acid [14] , arjungenin [15] , sericoside [16] , arjunglucoside I [15] and 3-O-β-Dglucopyranosyl-β-sitosterol [17] . Other compounds are 3-Omethylellagic acid (5), 3,3´-di-O-methylellagic acid, 3,3´,4-tri-Omethylellagic acid [18] , 4-(α-L-rhamnopyranosyl)ellagic acid [19] , 3-O-methyl-4-(α-L-rhamnopyranosyl)ellagic acid [18] , 4-O-(3´´,4´´-di-O-galloyl-α-L-rhamnopyranosyl)ellagic acid (6) [20] and diellagic lactone (7) [21] (Figure 1 carbon (δ C 180.9), two olefinic carbons (δ C 123.1 d, 143.3 s), one acetal carbon (δ C 92.4 d), three oxymethine carbons (δ C 85.7, 80.9, 61.7) and one oxymethylene carbon (δ C 69.6). The high field region had seven methyl, eight methylene, three methine and six quaternary carbons.
The carbon signals were indicative of an olean-12-en skeleton and correlated closely to those of sericic acid 3 [12] , except for the additional acetal methine carbon (δ C 92.4) and a secondary methyl carbon (δ C 19.9) of 1. Proton signals for the additional groups (δ H 5.02 d, J=5.2 Hz and δ H 1.25 d, J=5.2 Hz) showed COSY correlation, suggesting an ethylidene group of an acetal moiety. The ethylidene was assigned as connected to the oxygenated carbon atoms of C-3 and C-24 forming a six membered 1,3-dioxane moiety [4] , as confirmed by HMBC correlations made by H-3 (δ H 3.13) and H-24 (δ H 3.43) with the acetal carbon (δ C 92.4), as well as the downfield shift of C-3 and C-24 compared with those of sericic acid 3. Figure 2 shows some important HMBC and NOESY correlations that were used to confirm the structure.
In vitro antimicrobial and antiplasmodial activities were evaluated for all the compounds, except 1, which was isolated in small quantities as a minor compound. Antimicrobial activity was evaluated against the fungi Candida albicans, C. glabrata, C. krusei, Cryptococcus neoformans, and Aspergillus fumigatus, and the bacteria Staphylococcus aureus, methicillin-resistant S. aureus (MRS), Escherichia coli, Pseudomonas aeruginosa, and Mycobaterium intracellulare (see Table 2 ). Activity was observed for ellagic acid derivatives 5, 6 and 7, as well as for the triterpene arjunic acid (2) , and was stronger towards C. glabrata compared with other Candida species. The most potent activity observed was for diellagic lactone 7 with an IC 50 of 0.32 µg/mL. The antiplasmodial activity was evaluated against chloroquine sensitive (D6) and chloroquine resistant (W2) strains of Plasmodium falciparum. Results are summarized in Table 3 . Activity was observed for 4 and 6, both of which have galloyl group(s). All compounds tested were not cytotoxic to VERO cells, a mammalian cell line. 
Extraction and isolation:
Dried and pulverized stem bark (0.6 Kg) was extracted by cold percolation at room temperature using 1:1 CH 2 Cl 2 /MeOH (3×2 L, each 24 h), followed by 100% methanol (1×2 L, 24 h). The filtrates were concentrated in a rotory evaporator and combined to give 5 g of black-brown gummy extract, which was suspended in methanol/water (2:8, 100 mL) and partitioned successively with n-hexane and EtOAc (2×200 mL each) to give Characterization and bioactivities of compounds from Terminalia brownii Natural Product Communications Vol. 8 (6) 2013 763 0.2 g of n-hexane extract, 2.1 g of ethyl acetate extract and 2.2 g of residual water extract. Antiplasmodial assays showed that the activity was concentrated in the ethyl acetate fraction, which was chosen for isolation of compounds. 
Identification of the compounds:
The known compounds (vide infra) were identified using NMR spectroscopic methods ( 1 H NMR, 13 C NMR, DEPT, COSY, HSQC), and MS, as well as by direct comparison with published spectroscopic data and structures [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . ( 
3β,24-O-Ethylidenyl-2α,19α-dihydroxyolean-12-en-28-oic acid

Antiplasmodial assay:
The in vitro antiplasmodial activity was measured using the assay protocol based on a colorimetric method that determines the parasitic lactate dehydrogenase (pLDH) activity [22, 23] . The assay was performed in a 96-well microplate and included two P. falciparum strains [Sierra Leone D6 (chloroquinesensitive) and Indochina W2 (chloroquine-resistant)]. DMSO, artemisinin and chloroquine were included in each assay as vehicle and drug controls, respectively.
